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Tc-3,3-diphosphono-1,2-propanodicarboxylic acid Cardiac transthyretin amyloidosis (ATTR) is a progressive and fatal form of amyloidosis caused by extracellular deposition of amyloid fibrils from liver-derived transthyretin (TTR) (1) . ATTR may be hereditary, in which genetic variants of TTR are implicated and are associated with the overlapping syndromes of familial amyloid cardiomyopathy and familial amyloid polyneuropathy, or it may be sporadic, associated with deposition of wild-type transthyretin as amyloid. The latter predominantly involves the hearts of older individuals and the disorder is also known as senile systemic amyloidosis. At autopsy, cardiac ATTR amyloid deposition can be remarkably common, present in 8% to 16% of individuals older than 80 years (2) . Conversely, cardiac ATTR is rarely diagnosed during life, but greater awareness and better imaging methods have increased its recognition lately among elderly patients with left ventricular hypertrophy (LVH) and in specific at-risk ethnic populations (3).
Diagnosing cardiac ATTR amyloidosis is challenging. A suggestive constellation of electrocardiography, echocardiography, and biomarker findings are present in advanced disease, but interpretation may be confounded by common comorbidities such as hypertensive heart disease, diabetes, diastolic dysfunction, and renal disease (4) (5) (6) . Bone tracer scintigraphy, using as a sensitive tool for the identification of cardiac ATTR (7) (8) (9) . However, this nuclear medicine method is typically only performed to confirm ATTR when a clinical suspicion exists, as it does not provide information on any of the other differentials of LVH, cardiac morphology, or function, and is semi-quantitative only (10) , a limitation given the development of therapies able to stop or remove cardiac amyloid deposits (9, 11) .
In the last decade, cardiac magnetic resonance (CMR) has emerged as a robust imaging technique that provides detailed information about the presence, location, and distribution of hypertrophy, as well as visualization of cardiac amyloid infiltration with late gadolinium enhancement (LGE) imaging and measurement of cardiac amyloid burden with T1 mapping and extracellular volume (ECV) (12) (13) (14) (15) (16) (17) (18) . One retrospective study in patients with cardiac amyloidosis (n = 51) suggested that a high proportion of patients have morphological phenotypes that differ from the classical description of concentric symmetric hypertrophy (19) but the amyloidosis type was not specified. No study has assessed the morphology in a large cohort of patients with ATTR. ECV has been shown to be an important marker of prognosis in patients with amyloid light-chain (AL) amyloidosis, but its prognostic significance has never been assessed in patients with ATTR.
The aim of this study was to examine the CMR morphological phenotypes and tissue characterization findings in ATTR, to correlate these with clinical outcomes, and compare these findings with AL amyloidosis.
METHODS

Ethical approval was granted by the University College London/University College London
Hospitals Joint Committees on the Ethics of Human Research Committee and all participants provided written informed consent.
A total of 342 subjects were prospectively recruited between 2011 and 2015. The study population underwent comprehensive clinical evaluation and follow-up at the National Amyloidosis Centre, London, and comprised the 3 groups described below. Patients were systematically followed-up until October 4, 2016, the date of censor. Cardiac AL amyloidosis was determined on the basis of international consensus criteria (20) , and 50 consecutive patients with cardiac AL amyloidosis (37 male; age 63 ± 10 years) were recruited as a comparator group.
Subjects with contraindications to CMR included a glomerular filtration rate <30 ml/min.
CMR PROTOCOL.
All participants underwent standard CMR on a 1.5-T clinical scanner. A standard volume and LGE study was performed. The gadolinium-based contrast agent used was 0.1 mmol/kg of gadoterate meglumine.
LGE imaging was acquired using magnitude reconstruction in all patients and phase-sensitive inversion recovery reconstruction (PSIR) in 82% of patients. For native T1 and post-contrast mapping, basal and mid-ventricular short-axis and 4-chamber long-axis images were acquired using the modified look-locker inversion recovery (MOLLI) or shortened MOLLI sequence after regional shimming, as previously described (21) . After the bolus of gadoterate meglumine and standard LGE imaging (standard fast low-angle shot inversion recovery or balanced steady state free precession sequence with magnitude reconstruction and PSIR reconstruction), the T1 measurement was repeated with the MOLLI or shortened MOLLI sequence (22) . In 17 patients with ATTR, post-contrast T1 map acquisition was not performed; 5 patients requested to terminate the scan early and 12 had claustrophobia.
CMR IMAGE ANALYSIS.
All CMR images and maps were analyzed offline. The presence of LVH was defined as increased left ventricular (LV) mass based on age-and sex-indexed reference values. Asymmetric septal hypertrophy was defined as the ratio between the septal and posterior wall >1.5 (19) . Asymmetric septal hypertrophy comprised, in turn, 2 different patterns:
1) sigmoid septum, with the septum being concave to the LV cavity and a prominent basal septal bulge; and 2) reverse septal contour with an abnormal convexity of the septum toward the LV cavity (23, 24) . The ratio between the septal and posterior wall ≤1.5 and increased mass was considered symmetric concentric LVH. Before our adoption of PSIR for all amyloidosis patients, because myocardial nulling can be difficult in the presence of amyloid, any confusion with magnitude reconstruction images was resolved by selecting the images that most matched the post-contrast T1 maps, with "bright"
LGE expected to correlate with areas of the lowest postcontrast T1 (i.e., the highest gadolinium concentration, the highest interstitial expansion).
The LGE pattern was classified into 3 groups according to the degree of transmurality: group 1, no LGE; group 2, subendocardial LGE (when there was global subendocardial but no transmural LGE); and group 3, transmural LGE (when the LGE was extending transmurally).
Thus, a patient with basal transmural LGE but apical subendocardial LGE would be classified as transmural
LGE (25). 
RESULTS
The details of the 342 subjects are shown in V30M (n = 8); S77Y (n = 2); and E54G, E54L, E89K, D38Y, D39V, E89K, V20I, F44L, G89L
and L12P in 1 case each. The mutations among the possible cardiac amyloidosis subjects were: S77Y (n = 3) and V30M, I107F, E54G, G47V, and I84S in 1 case each. Finally, the mutations among the mutation carriers were: T60A (n = 6); V30M (n = 5); and S77Y (n = 1).
MORPHOLOGICAL PHENOTYPES. Asymmetric septal hypertrophy, defined as the ratio
between the septal and posterior wall >1.5 (19, 28) , was the most common form of ventricular remodeling in ATTR, being present in 79% of patients with cardiac ATTR. The pattern of asymmetric septal hypertrophy was divided into the morphological subtypes of sigmoid septum (55%) and reverse septal contour (24%). Symmetric concentric LVH, considered typical for amyloidosis, was present in only 18% of patients with ATTR (Figure 1 ). Tc-DPD scintigraphy) had no LVH (2 with
ATTRm and 5 with wild-type ATTR).
Prevalence of asymmetric septal hypertrophy was significantly higher in ATTR compared to patients with cardiac AL amyloidosis (79% vs. 14%; p < 0.001), where the most common form of ventricular remodeling was symmetric concentric LVH (34 patients [68%]), followed by asymmetric pattern with sigmoid septal contour in 7 patients (14%). The asymmetric pattern with reverse septal contour was not found in the AL amyloidosis cohort. Nine patients (18%) with cardiac AL amyloidosis had no LVH.
TISSUE CHARACTERIZATION FINDINGS.
In patients with cardiac amyloidosis, LGE was always present and the pattern of LGE was typical for amyloidosis, being diffuse subendocardial
LGE in 29% of patients and transmural LGE in 71% (Figure 2) . Right ventricular (RV) LGE was extremely frequent, being present in 96% of patients. There was no difference in LGE prevalence between wild-type ATTR and ATTRm (transmural LGE 71% vs. 72% and subendocardial LGE 29% vs. 28%; p > 0.05 for both). As previously reported, the prevalence of transmural LGE and RV LGE was significantly higher in ATTR compared to AL (transmural LGE 71% vs. 50% and RV LGE 96% vs. 77%; p < 0.01 for both). In this population, transmural
LGE was not associated with a worse prognosis than subendocardial LGE (p = 0.327). Tc-DPD grade 1). The rest of the patients showed no LGE (n = 10), subendocardial LGE with ischemic pattern (n = 2), and mid wall LGE in the basal infero-lateral wall (n = 2) (Online Figures 1 and 2) . The 3 patients with Se77Tyr and 99m
Tc-DPD grade 1 had typical LGE pattern (1 presented subendocardial LGE and 2 transmural LGE). The clinical, morphological, and functional features of these 3 patients were also in keeping with cardiac amyloidosis on echocardiogram, ECV measurements, and biomarkers (Figure 3) , suggesting that they have less DPD uptake than they should given the amyloid burden.
There was good correlation between ECV and cardiac uptake on symmetric septal hypertrophy could play an important role in the misdiagnosis of ATTR. One possibility that could explain why this pattern occurs is related to differential rates of effective cell hypertrophy in AL versus ATTR. Our prior work highlighted that in ATTR, total cell mass increased, whereas it remained the same in AL (29) . It is possible that while infiltration was global, a triggered myocyte response differentially induced septal hypertrophy. Another possibility is that AL patients died before their total infiltration achieved the levels found in ATTR, so they were unable to get to the reverse septal contour stage.
We found that in all patients with cardiac ATTR, the pattern of late gadolinium enhancement was always typical of cardiac amyloidosis, with a subendocardial or transmural
LGE pattern (25, 30) . Subendocardial LGE was found in 29% and the remainder (71%) showed transmural LGE. RV LGE was present in 96% of patients. This confirmed previous reports on the high prevalence of transmural LGE and RV LGE in ATTR (31), but it also highlighted the important role that CMR could have in diagnosing this disease. The typical appearance of LGE in patients with cardiac ATTR with subendocardial or transmural LGE has the potential to revolutionize the diagnostic pathway of this disease, as CMR is currently the diagnostic reference standard for the differential diagnosis of cardiomyopathies with hypertrophic phenotype.
With the exception of patients with the Se77Tyr variant, none of the patients with suspected rather than proven cardiac ATTR (defined as grade 1 cardiac uptake on Tc-DPD scintigraphy that seemed to show a similar sensitivity.
STUDY LIMITATIONS.
This study has several limitations. We used the proposed noninvasive criteria for ATTR (9), meaning cardiac biopsy was performed only in a minority of patients. Two different T1 mapping techniques were used during the period in which these patients were recruited and a wide range of TTR mutations were included in the analysis. 
CONCLUSIONS
FIGURE LEGENDS CENTRAL ILLUSTRATION CMR in ATTR
In this study, cardiac magnetic resonance (CMR) with extracellular volume (ECV) was used to characterize cardiac involvement as it related to outcomes in cardiac transthyretin amyloidosis (ATTR). The relationship between late gadolinium enhancement (LGE) patterns and ECV showed a typical correlation of very high ECV values and subendocardial or transmural LGE.
Asymmetric septal left ventricular hypertrophy (LVH) was present in 79% of patients with ATTR, more than 5 times higher than that seen in patients with cardiac amyloid light-chain amyloidosis. In patients with ATTR, ECV was independently correlated with mortality.
FIGURE 1 Morphology Patterns in ATTR
In 4 patients with cardiac transthyretin amyloidosis (ATTR), 4-chamber cine image in diastole and corresponding late gadolinium enhancement (LGE) illustrate asymmetric hypertrophy with sigmoid septal contour and transmural LGE; asymmetric hypertrophy with reverse septal contour and transmural LGE; symmetric hypertrophy pattern and transmural LGE; and no left ventricular hypertrophy (LVH) and subendocardial LGE.
FIGURE 2 LGE Patterns Correlating with T1 and ECV Measurements
Images shown include 4-chamber cine, corresponding LGE image with phase sensitive reconstruction, native T1 maps, and extracellular volume (ECV) maps in 3 patients with ATTR.
The patient with no LGE has normal native T1 and ECV maps; the patient with subendocardial
LGE shows borderline T1 values and high ECV values; and in the patient with transmural LGE, very high native T1 values and very high ECV values are seen. Other abbreviations as in Figure   1 . 
FIGURE 4 ECV and Cardiac Uptake
As seen in this correlation between ECV and grade of abnormal cardiac uptake on Tc-DPD scintigraphy, only patients with the Se77Tyr variant had high ECV measurements with grade 1 abnormal uptake. Abbreviations as in Figures 2 and 3.
FIGURE 5 Survival Analysis
As seen via Kaplan-Meier curves, ECV was independently correlated with mortality in all patients with ATTR as well as those hereditary and wild-type ATTR. Abbreviations as in Figures   1 and 2 . 
